Retatrutide
For laboratory research only — not for human consumption. Sold and shipped by Peptide Plus, not Alphapeptide. Use code ALPHA10 at checkout. Alphapeptide earns a commission on referred sales.
How it’s studied.
A 39-amino-acid synthetic peptide that is a triple agonist of GLP-1, GIP, and glucagon receptors. In research literature, retatrutide is studied for concurrent incretin signaling, lipolysis through the glucagon arm, and hepatic glucose modulation. Published clinical trials report substantial body weight reductions of 24–30% over 48–68 weeks alongside improvements in liver fat and cardiovascular markers.
Retatrutide is a 39-amino-acid linear synthetic peptide developed as the first triple agonist of GLP-1, GIP, and glucagon receptors. The fatty-acid linker enables albumin binding and a ~6-day plasma half-life. It represents one of the most extensively studied next-generation incretin compounds in metabolic research.
Half-life note · Approximately 6-day plasma half-life via fatty-acid albumin binding.
Research areas.
- 01
Triple-agonist receptor binding research
- 02
Metabolic pharmacology studies
- 03
Body weight regulation research
- 04
Hepatic fat reduction studies
Reported in literature: 0.5–12 mg weekly titration (clinical research, not for human use)
Pre-filled defaults for Retatrutide.
- Concentration
- 2.50mg/mL
- Draw on U-100
- 480units
- Volume / dose
- 4.800mL
- Doses / vial
- 0
Assumes 27-gauge insulin syringe, U-100 markings. Verify before use.
Open in calculator